An observational study in Ebola Virus Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 4 sites in Liberia. Open to participants aged 3 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-08-22.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Background:
Genes are instructions that tell the body how to work and grow. They can affect how the body responds to infection. Researchers want to learn more about genes that affect how the body responds to the Ebola virus. Some people with Ebola get very sick and die. Others do not. The research may lead to better treatments for Ebola virus and other germs.
Objective:
To look for genes that may be related to a person s chance of getting very sick after coming in contact with the Ebola virus.
Eligibility:
People at least 3 years of age who either:
Had Ebola
Had close contact with someone who had Ebola
Were in an Ebola vaccine study
Design:
Participants will have a small amount of blood taken from an arm vein by a needle.
Researchers will collect participants data from other vaccine studies they may have been in.
Participants may be asked questions about their health and social history.
Some participants will have their blood tested for the infection syphilis and HIV, the virus that causes AIDS. Participants will be told the results and will get help finding care, if necessary.
Some participants will have their blood sample tested to see if they have had Ebola in the past.
Blood samples will be stored for future research. They will be marked with a code but not with participants names.
The 2013-2015 Ebola Virus outbreak in Western Africa was unprecedented in size and geographic scope. There were over 28,000 cases and 11,000 deaths. During and following the outbreak, it became evident that spectrum of disease being observed in the communities and the Ebola treatment units was much broader than previously thought. In this study, we aim to identify host genetic factors that underlie the observed variation in disease susceptibility, severity, clinical sequelae, viral persistence, and serological response. We will enroll EVD survivors, close contacts of survivors, EVD healthcare workers, and individuals who have received investigational Ebola vaccines (population controls), and collect a blood sample, HIV/syphilis infection status, demographics, and medical history from participants.
Most subjects will complete study participation after a single study visit; subjects having Ebola serology and/or HIV/syphilis testing done as part of this study will return for one or two follow-up visits to receive their HIV/syphilis test results and post-test counseling and Ebola serology results. We will genotype participants and compare results between cohorts to address the study aims. This may provide insight into pathogenesis and host immunity and potentially suggest new methods of intervention.
104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.
This study's enrollment of 4,830 is above the median of 266 across 16 observational studies indexed under Hemorrhagic Fever, Ebola.
Browse Hemorrhagic Fever, Ebola studies →National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,446 studies on the registry; 179 are open to participants now.
Of its 405 completed or terminated interventional studies of FDA-regulated products, 302 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
EVD survivors, close contacts of survivors, EVD healthcare workers, and individuals who have received investigational Ebola vaccines (population controls)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EVD Survivor:
Direct EBOV exposure control:
Meets at least 1 of the following:
No known EBOV exposure population controls:
Meets at least 1 of the following:
EXCLUSION CRITERIA:
Direct EBOV exposure risk controls
EVD fatal cases
EVD survivor cases
No known EBOV exposure population controls
Identify genetic variation associated with risk of contracting clinical Ebola Virus Disease when directly exposed to the Ebola virus
Disease susceptibility and specific symptoms following EBOV infection
Time frame: At Enrollment
Identify genetic variation associated with mortality from Ebola VirusDisease
Disease susceptibility and specific symptoms following EBOV infection
Time frame: At Enrollment
Identify genetic variation associated with post recovery Ebola viral RNA persistence in bodily fluids
Time frame: At Enrollment
Identify genetic variation associated with the presence of uveitis among EVD survivors identified in PREVAIL III
Time frame: At Enrollment
Identify genetic variation associated with the magnitude and duration of anti-EBOV IgG titer in both EVD cases and vaccine recipients enrolled in PREVAIL I or PREVAC/PREVAIL V trials
Time frame: At Enrollment
Ran from Sep 2017 to primary completion in Feb 2019, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID) →